Effect of <italic style="font-style: italic">Huatan Sanjie Formula</italic> （化痰散结方） on Thyroid Angiogenesis and VEGFA/VEGFR2 Signaling Pathway in Graves' Disease Model Mice

MA Wenxin; ZHU Xiaoyun; WANG Chengna; XU Jing; LIU Ximing; TANG Yang

doi:10.13288/j.11-2166/r.2024.19.012

您当前的位置：

首页 >

文章列表页 >

Effect of Huatan Sanjie Formula （化痰散结方） on Thyroid Angiogenesis and VEGFA/VEGFR2 Signaling Pathway in Graves' Disease Model Mice

更新时间：2024-09-26

- Effect of Huatan Sanjie Formula （化痰散结方） on Thyroid Angiogenesis and VEGFA/VEGFR2 Signaling Pathway in Graves' Disease Model Mice
- Journal of Traditional Chinese Medicine Vol. 65, Issue 19, Pages: 2025-2031(2024)
- 作者机构：
  
  1.北京中医药大学，北京市朝阳区北三环东路11号，100029
  2.中国中医科学院广安门医院
  3.北京中医药大学东直门医院
- 作者简介：
- 基金信息：
- DOI：10.13288/j.11-2166/r.2024.19.012
  CLC：
- Received：09 March 2024，
  
  Revised：2024-07-18，
  
  Published：02 October 2024
- 稿件说明：
移动端阅览
马文欣,朱晓云,王程娜等.化痰散结方对Graves病模型小鼠甲状腺血管新生及VEGFA/VEGFR2信号通路的影响[J].中医杂志,2024,65(19):2025-2031.

MA Wenxin,ZHU Xiaoyun,WANG Chengna,et al.Effect of Huatan Sanjie Formula （化痰散结方） on Thyroid Angiogenesis and VEGFA/VEGFR2 Signaling Pathway in Graves' Disease Model Mice[J].Journal of Traditional Chinese Medicine,2024,65(19):2025-2031.
马文欣,朱晓云,王程娜等.化痰散结方对Graves病模型小鼠甲状腺血管新生及VEGFA/VEGFR2信号通路的影响[J].中医杂志,2024,65(19):2025-2031. DOI： 10.13288/j.11-2166/r.2024.19.012.

MA Wenxin,ZHU Xiaoyun,WANG Chengna,et al.Effect of Huatan Sanjie Formula （化痰散结方） on Thyroid Angiogenesis and VEGFA/VEGFR2 Signaling Pathway in Graves' Disease Model Mice[J].Journal of Traditional Chinese Medicine,2024,65(19):2025-2031. DOI： 10.13288/j.11-2166/r.2024.19.012.

摘要

目的

从甲状腺血管新生角度探讨化痰散结方治疗Graves病的可能作用机制。

方法

36只BALB/c雌性小鼠随机分为正常对照组9只和造模组27只，造模组小鼠以Ad-TSHR289腺病毒2.0×10

PFU/ml胫前肌肉注射100 μl构建Graves病小鼠模型。免疫后第9周将造模成功小鼠随机分为模型组、甲巯咪唑组和化痰散结组，每组9只。甲巯咪唑组小鼠给予甲巯咪唑片5.2 mg/（kg·d）灌胃，化痰散结组小鼠给予化痰散结方相对生药量7.02 g/（kg·d）灌胃，正常对照组与模型组给予纯水0.1 ml/10 g灌胃。均每日灌胃1次，共计4周。放射免疫法检测各组小鼠血清中甲状腺素（T4）和促甲状腺素受体自身抗体（TRAb）含量，HE染色观察甲状腺病理改变情况，CD34免疫组化染色观察甲状腺组织血管形态并对微血管密度（MVD）计数，Western-blot法检测小鼠甲状腺中血管内皮生长因子A（VEGFA）和血管内皮生长因子受体2（VEGFR2）蛋白表达。

结果

与正常对照组比较，模型组小鼠甲状腺体积明显增大，存在过度充血，病理显示甲状腺滤泡增生显著，上皮细胞呈柱状且增殖明显，滤泡体积增大；血清中T4、TRAb水平上升，甲状腺MVD计数增多，甲状腺VEGFA、VEGFR2蛋白表达上调（

＜0.01）。与模型组比较，甲巯咪唑组和化痰散结组小鼠的甲状腺明显减小，充血情况有所改善，病理显示甲状腺滤泡增生和上皮细胞增殖减轻，滤泡

边缘光滑、内凸明显减少；血清T4、TRAb水平降低，甲状腺MVD计数减少，甲状腺VEGFA、VEGFR2蛋白表达量显著下调（

＜0.05或

＜0.01）。甲巯咪唑组和化痰散结组各指标差异均无统计学意义（

＞0.05）。

结论

化痰散结方可能通过下调甲状腺VEGFA/VEGFR2信号通路从而抑制甲状腺血管新生，改善Graves病甲状腺肿大和功能亢进。

Abstract

Objective

To investigate the possible mechanism of

Huatan Sanjie Formula

（化痰散结方， HSF） in treating Graves' disease （GD） from the perspective of thyroid angiogenesis.

Methods

Thirty-six BALB/c female mice were randomly divided into a normal control group （n=9） and a modeling group （n=27）. Mice in the modeling group were injected with 2.0×10

PFU/ml of Ad-TSHR289 adenovirus into the tibialis anterior muscle to build GD model. Nine weeks after immunization， the successfully modeled mice were randomly divided into model group， methimazole （MMI） group and HSF group， with 9 mice in each group. The MMI group was given 5.2 mg/（kg·d） of methimazole tablets by gavage， while the HSF group was given HSF at a relative crude drug dosage of 7.02 g/（kg·d） by gavage. The normal control group and the model group were given 0.1 ml/10 g of pure water by gavage. All groups were administered intragastrically once a day for a total of 4 weeks. The levels of thyroxine （T4） and thyrotropin receptor autoantibodies （TRAb） in serum were detected by radioimmunoassay， while the pathological changes of the thyroid gland were assessed by HE staining. The vascular morphology of thyroid tissue was observed by CD34 immunohistochemical staining， and the microvessel density （MVD） was counted. The protein expression of vascular endothelial growth factor A （VEGFA） and vascular endothelial growth factor receptor 2 （VEGFR2） in thyroid was detected by Western-blot.

Results

Compared to those in the normal control group， the thyroid volume of the mice in the model group significantly increased with excessive congestion

， and the pathology showed significant thyroid follicular hyperplasia， columnar and proliferated epithelial cells， and enlarged follicle size； serum T4 and TRAb significantly increased， as well as the count of thyroid MVD， and the protein expressions of thyroid VEGFA and VEGFR2 （

＜0.01）. Compared to those in the model group， the thyroid glands of the mice in the MMI group and the HSF group were significantly reduced， and the congestion was improved； pathology showed that thyroid follicular hyperplasia and epithelial cell proliferation were reduced， with smooth edges of the follicles and the significantly reduced inward protrusion； serum T4 and TRAb significantly decreased， as well as the thyroid MVD， thyroid VEGFA and VEGFR2 protein expressions （

＜0.05 or

＜0.01）. There was no significant difference in all indicators between the MMI group and the HSF group （

＞0.05）.

Conclusion

HSF may inhibit thyroid angiogenesis by down-regulating thyroid VEGFA/VEGFR2 signaling pathway， thereby improving goitre and hyperfunction in GD mice.

关键词

Keywords

references

LANE LC ， CHEETHAM TD ， PERROS P ， et al . New therapeutic horizons for Graves' hyperthyroidism ［J］. Endocr Rev ， 2020 ， 41 （ 6 ）： 873 - 884 .

JANG JY ， CHOI SY ， PARK I ， et al . VEGFR2 but not VEGFR3 governs integrity and remodeling of thyroid angiofollicular unit in normal state and during goitrogenesis ［J］. EMBO Mol Med ， 2017 ， 9 （ 6 ）： 750 - 769 .

《中成药治疗优势病种临床应用指南》标准化项目组 . 中成药辅助治疗甲状腺功能亢进症（Graves病）临床应用指南（2021年）［J］. 中国中西医结合杂志， 2022 ， 42 （ 9 ）： 1029 - 1039 .

于雪婷，汤阳，王文方，等 . 甲状腺肿大与“气、痰、瘀”的关系论述及临床思考［J］. 中医药导报， 2018 ， 24 （ 21 ）： 18 - 20 .

马文欣，刘金民，汤阳，等 . 从抑制血管新生探讨中医治疗Graves病的调血脉之法［J］. 中医杂志， 2021 ， 62 （ 14 ）： 1224 - 1227 .

孟祥 . 甲亢宁胶囊对Graves病减毒增效作用的临床观察［D］. 北京：北京中医药大学， 2017 .

石霞，朱晓云，刘喜明 . 近5年毒性弥漫性甲状腺肿中医病机及辨证论治研究概述［J］. 环球中医药， 2020 ， 13 （ 6 ）： 1119 - 1124 .

夏枯草口服液临床应用共识专家组 . 夏枯草口服液治疗甲状腺肿大/结节类甲状腺疾病临床应用专家共识［J］. 中草药， 2020 ， 51 （ 8 ）： 2082 - 2087 .

袁泉 . 化痰散结法干预Graves病小鼠甲状腺肿大与功能亢进的免疫调控研究［D］. 北京：北京中医药大学， 2017 .

朱晓云，刘丽娟，杨东甲，等 . 过表达人TSHR-A亚单位的重组腺病毒Ad-TSHR289/6xHis载体构建与鉴定［J］. 重庆医科大学学报， 2014 ， 39 （ 4 ）： 524 - 528 .

TANG Y ， ZHU X ， FENG H ， et al . An improved mouse model of Graves disease by once immunization with Ad-TSHR289 ［J］. Endocr J ， 2019 ， 66 （ 9 ）： 827 - 835 .

汤阳，朱晓云，冯慧，等 . 重组腺病毒Ad-TSHR289注射诱导Graves病小鼠模型［J］. 山东医药， 2019 ， 59 （ 6 ）： 49 - 52 .

魏伟，吴希美，李元建 . 药理实验方法学［M］. 北京：人民卫生出版社， 2010 ： 1698 .

COLIN IM ， DENEF JF ， LENGELÉ B ， et al . Recent insights into the cell biology of thyroid angiofollicular units ［J］. Endocr Rev ， 2013 ， 34 （ 2 ）： 209 - 238 .

VITA R ， DI BARI F ， PERELLI S ， et al . Thyroid vascularization is an important ultrasonographic parameter in untreated Graves' disease patients ［J］. J Clin Transl Endocrinol ， 2019 ， 15 ： 65 - 69 . doi： 10.1016/j.jcte. 2019. 01.001 http://dx.doi.org/10.1016/j.jcte.2019.01.001 .

FERRARA N . VEGF-A： a critical regulator of blood vessel growth ［J］. Eur Cytokine Netw ， 2009 ， 20 （ 4 ）： 158 - 163 .

卢文丽，方肇勤，潘志强，等 . 基于芯片数据分析同病异证H22荷瘤小鼠甲状腺生长因子表达特征［J］. 南京中医药大学学报， 2012 ， 28 （ 2 ）： 147 - 151 .

MALKOMES P ， OPPERMANN E ， BECHSTEIN WO ， et al . Vascular endothelial growth factor：marker for prolife-ration in thyroid diseases？［J］. Exp Clin Endocrinol Diabetes ， 2013 ， 121 （ 1 ）： 6 - 13 .

SATO K ， YAMAZAKI K ， SHIZUME K ， et al . Stimulation by thyroid-stimulating hormone and Grave's immunoglobulin G of vascular endothelial growth factor mRNA expression in human thyroid follicles in vitro and flt mRNA expression in the rat thyroid in vivo ［J］. J Clin Invest ， 1995 ， 96 （ 3 ）： 1295 - 1302 .

冒婧敬，相萍萍，刘超 . Graves病动物模型构建的研究进展［J］. 实用临床医药杂志， 2021 ， 25 （ 9 ）： 113 - 116，122 .

汤阳 . 化痰散结法干预Graves病小鼠免疫耐受及其调控失常的作用机制研究［D］. 北京：中国中医科学院， 2019 .

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effects of Huoxue Yiqi Fang （活血益气方） and its Disassembled Prescription on Vascular Endothelial Growth Factor and its Upstream Regulation Factor miR-126 in Rat Myocardial Infarction Border Area

Effects of Huatan Sanjie Formula （化痰散结方） on Tumor Tissue Stiffness and the Integrin β1/FAK/YAP Mechanotransduction Signaling Pathway in Triple Negative Breast Cancera Model Mice

Effect of Wenyang Shengji Ointment （温阳生肌膏） on MGO Content and HIF-1a/VEGF Pathway in Wound Tissue of Diabetic Wound Model Rats with Yin Syndrome

Effect of Collagen Loading with Shengji Yuhong Ointment （生肌玉红胶原） on Angiogenesis in Model Rats with Hind Limb Ischemic Wound

The Effect of Biejia Jian Wan （鳖甲煎丸） on Angiogenesis of vitro Cultured Aorta Ring in Rats

Related Author

ZHENG Ruiling

CHEN Meng

WU Aiming

LOU Lixia

ZHAO Yizhou

CHAI Limin

ZHAO Jiuli

LYU Xiying

Related Institution

School of Preclinical Medicine,Beijing University of Chinese Medicine

Dongzhimen Hospital,Beijing University of Chinese Medicine

Cancer Diagnosis and Treatment Center，Weifang Hospital of Traditional Chinese Medicine

School of Traditional Chinese Medicine，Macau University of Science and Technology

School of Traditional Chinese Medicine，Shandong Second Medical University

Address：No.16, Nanxiao street, Dongzhimen, Dongcheng District, Beijing Postal code：100700
Tel：010-64035632 Email：jtcmcn@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19 京公网安备11010102007558号
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰

Effect of Huatan Sanjie Formula （化痰散结方） on Thyroid Angiogenesis and VEGFA/VEGFR2 Signaling Pathway in Graves' Disease Model Mice

DOI：10.13288/j.11-2166/r.2024.19.012

摘要

Abstract

关键词

Keywords

references